NIKKEI 225
38,044.39 +415.91 (+1.11%) HANG SENG
17,699.41 +414.87 (+2.40%) CRUDE OIL
84.02 +0.45 (+0.54%) GOLD FUTURES
2,348.10 +5.60 (+0.24%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,446.20 +93.95 (+0.18%)
Guardant Health, Inc. (GH)
After hours:
| Previous close | 18.10 |
| Open | 17.71 |
| Bid | 17.14 x 1300 |
| Ask | 17.18 x 300 |
| Day's range | 16.95 - 17.85 |
| 52-week range | 15.81 - 41.06 |
| Volume | |
| Avg. volume | 1,994,511 |
| Market cap | 2.089B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.28 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 37.53 |
ZacksWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Business WireFDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
PALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.
- Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
PALO ALTO, Calif., April 18, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
